August 1, 2016 / 12:43 PM / a year ago

BRIEF-Aeterna and Rafa Laboratories sign license agreement for Zoptrex in Israel

1 Min Read

Aug 1 (Reuters) - Aeterna Zentaris Inc

* Aeterna Zentaris and Rafa Laboratories sign exclusive license agreement for Zoptrex in Israel

* Company expects to complete phase 3 clinical trial in Q3 of 2016

* Company and Rafa have also entered into a supply agreement

* Entitled to receive a non-refundable upfront payment in consideration for license to Rafa of intellectual property related to Zoptrex

* Company will supply Zoptrex to Rafa for duration of license agreement Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below